RxDoctor Payments DataLook up a doctor →

Christina Szot, MD

Pulmonary Disease · Reno, NVNPI 1326023755

Payments from drug & device makers

$15,849in general payments, 2019–2025

Across 333 payments — averaging $47.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$10K
  • GSK$959
  • Regeneron Healthcare Solutions, Inc.$348
  • Inspire Medical Systems, Inc.$310
  • Calliditas Therapeutics US Inc.$283
  • Amgen$279
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$6,36397%
  • Education$2173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,849 in reported general payments places this provider in the 80th percentile of 84 pulmonary disease providers in Nevada.

See all pulmonary disease providers in Nevada

Medicare billing

Part B allowed, 2024
$126,374
Medicare patients
482
Services billed
1,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter203$175,326
Breo ElliptaFluticasone/Vilanterol130$77,826
Breztri AerosphereBudesonide/Glycopyr/Formoterol80$54,764
Spiriva RespimatTiotropium Bromide38$25,655
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$23,492
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$22,088
SymbicortBudesonide/Formoterol Fumarate52$18,694
Advair HfaFluticasone Propion/Salmeterol15$7,982
Albuterol Sulfate HfaAlbuterol Sulfate152$4,600
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$4,140
Incruse ElliptaUmeclidinium Bromide12$4,140
Arnuity ElliptaFluticasone Furoate17$3,472
Advair DiskusFluticasone Propion/Salmeterol14$3,281
BreynaBudesonide/Formoterol Fumarate14$2,282
Wixela InhubFluticasone Propion/Salmeterol15$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$959$282,853400 claims
AstraZenecaBreztri Aerosphere, Symbicort$9,696$73,458132 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$226$49,14757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 84 pulmonary disease providers in Nevada.

Other pulmonary disease in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →